ERBB2 and cancer: A recent analysis found that Pertuzumab, used to treat HER-2 positive metastatic breast cancer and associated with an improvement in median overall survival of over one year was not cost effective at $472,668 per quality-adjusted-life-year [25]. Figure 2 shows the proportion of patients with new cancer diagnoses, in cancer survivorship and dying from cancer in comparison to the proportion of annual expenditure in 2010 US dollars for each group [26]. As demonstrated in the figure, a small proportion of patients dying from cancer represents the majority of annual expenditure.